Zambon Switzerland, a company based in Cadempino-Ticino since 1965, is the swiss affiliate of Zambon Group an Italian Family business that has been operating in the pharmaceutical and chemical business for over 100 years. Founded in Vicenza in 1906, today the group operates in 15 subsidiaries in Europe, South America and Asia with more than 2’654 employees and sells its products in 73 countries.
In the Swiss plant the manufacturing activities are focused on oral forms - granulated and effervescent - and injectable as carbapenemic.
The Swiss plant can be considered a centre of excellence for the production of Carbapenemics thanks to the partnership with Pfizer.
The total productive capacity is currently about 90 million of pieces. The capacity for granulated forms in sachets, puts Zambon Switzerland among major worldwide producers. The plant is approved by Swissmedic (Swiss Authority) with an EU mutual recognition as well as from FDA (American Authority) and ANVISA (Brazilian Authority).
The plant is certified according ISO 14001 international standards certification since 2004 The Swiss plant offers product and services with high added value, based on excellence of innovation and perfect execution, thanks to its strong culture and deep technology knowledge in the production for third parts and toll manufacturing, having the ability to satisfy the highest standards currently requested in the pharmaceutical world.
|T.: +41 91 960 41 11|
|F.: +41 91 966 43 51|
Main activities Licensing-In ● Licensing-Out ● Co-development ○ Drug Product CMO ●
Drug stages Phase I - Phase III ○ Registration ● Market ●
Therapeutic areas Gastrointestinal ● Gynaecology ● Pain ● Respiratory ●
Markets CH ● EU Top 5 ● USA and Canada ● LATAM ● BRICS ● ASEAN ●
Drug product forms Injectable ● Oral (solid) ●
Drug substance type APIs (>200kgs/batch) ● Antibiotics ●
Other activities (non pharma) Distribution ●
Other CMO activities Co-development ●